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ABSTRACT 
The incidence of venous thromboembolism (VTE) and VTE-related morbidity and 
mortality increase with advancing age. Over the past decade, substantial advances in 
treatment of VTE have been made, most notably the introduction of direct oral 
anticoagulants (DOACs) which offer simple treatment regimens across a broad 
spectrum of VTE patients and have become the first-choice anticoagulants in many VTE 
patients. Even though elderly patients are underrepresented in clinical trials, 
extrapolation of overall study results to the elderly subpopulation appears justified for 
acute VTE treatment and for the choice of anticoagulant agent. In the elderly, DOACs 
are not only associated with a lower risk of bleeding but they even appear to be more 
efficacious than vitamin K antagonists in preventing recurrent VTE during the acute 
treatment period. The most challenging aspect of VTE management in elderly patients is 
determination of optimal treatment duration. The risk of bleeding increases with 
advancing age but also several risk factors for recurrent VTE after stopping 
anticoagulation are more frequent in the elderly. Clinical decision rules estimating risk of 
recurrent VTE and bleeding have limited utility in elderly patients. Shared decision 
making considering patient preferences and values is therefore crucial to help determine 
individual treatment duration in elderly patients. 
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INTRODUCTION 
Venous thromboembolism (VTE), defined as pulmonary embolism (PE) or deep 
vein thrombosis (DVT), is a common disease in the elderly population. The incidence of 
VTE increases exponentially with age and is 4-12 per 1000 person-years in persons 
aged 80 years and older, which reflects a 5 to 10-fold higher risk of developing VTE 
compared to persons aged 40 to 50 years [1]. While the incidence of DVT has remained 
stable or even decreased over time [2, 3], the incidence of PE has increased in both the 
younger and the elderly population in recent decades [3]. The latter is partly related to 
the widespread use of sensitive multi-detector computed tomography pulmonary 
angiography resulting in more frequent diagnosis of smaller, potentially insignificant PE 
than the use of single-detector computed tomography or ventilation-perfusion scan [4-6]. 
Not only the incidence of VTE but also clinical presentation, prognostic factors, and 
outcome rates differ between younger and older patients with acute VTE [7, 8]. 
Furthermore, evidence regarding optimal treatment of VTE in the elderly including first-
choice anticoagulant agent and duration of anticoagulation is limited because elderly 
patients were underrepresented in clinical trials [7, 9]. As a consequence, the 2016 
American College of Chest Physician (ACCP) and the 2019 European Society of 
Cardiology guidelines do not make specific recommendations for elderly patients, but 
only acknowledge the higher risk of bleeding in this population [10, 11]. 
Over the past decade, substantial advances in treatment of VTE have been made 
[12], most notably the introduction of direct oral anticoagulant (DOACs) which offer 
simple treatment regimens across a broad spectrum of VTE patients. In light of the 
significant proportion of elderly among patients with VTE and their distinct risk of VTE-
related outcomes, in this review, we summarize evidence of VTE treatment with DOACs 
in elderly patients and we discuss situations in which other anticoagulants may be 
preferred. 
 
DEFINITION OF THE ELDERLY AND ANALYSES FOR THIS REVIEW 
The US Census Bureau defines the elderly as the population aged 65 years and 
older; most other developed countries have accepted similar definitions. Definitions for 
the elderly in studies in the field of VTE are more heterogenous. Subgroup analyses of 
many recent pivotal randomized controlled trials used age 75 years as cut-off; in recent 
cohort studies cut-offs ranged from 60 to 80 years. In this review, we will report results 
using the definition of the pertinent reference. 
Amongst previously published evidence, we will also report pooled risk ratios of 
phase III DOAC trials for VTE treatment by age. Relative risks with corresponding 95% 
confidence intervals (CI) were calculated based on crude event numbers reported in the 
trial publications in which the intention-to-treat population was used for efficacy 
outcomes and the safety population for bleeding outcomes. If not available in the original 
publication, event numbers were extracted from a meta-analysis that published 
subgroup analyses based on additional information from the corresponding authors and 
sponsors of the study [13]. Pooled relative risks were calculated using the Mantel-
Haenszel method. The between-study variance was estimated using the DerSimonian-
Laird method, and heterogeneity reported with the I2 statistic. All analyses were 
performed in R, version 3.6.1 [14], by using the meta package, version 4.9-7 [15].  
PHARMACOKINETICS AND PHARMACODYNAMICS OF DIRECT ORAL 
ANTICOAGULANTS 
DOACs specifically target single steps in the coagulation pathway by direct 
inhibition of activated factor X (rivaroxaban, apixaban, and edoxaban) or thrombin 
(dabigatran). Rivaroxaban at doses of 15 or 20 mg daily requires to be taken with food 
as this increases its bioavailability (66% without food; 80-100% with food), which is not 
required for other DOACs [16]. Dabigatran is a pro-drug and it should not be crushed 
before ingestion as this results in a 75% increase of its bioavailability [16]. Rivaroxaban, 
apixaban, and edoxaban can be administered in crushed form if patients are unable to 
swallow tablets [17-19]. DOACs have a dual mode of elimination consisting of hepatic 
metabolization and renal excretion at different degrees depending on drug. The 
proportion of renal clearance to non-renal clearance of the absorbed DOAC is 27% for 
apixaban, 35% for rivaroxaban, 50% for edoxaban, and 80% for dabigatran [16]. 
Elimination half-lives in persons with normal kidney function range from 5-9 hours 
(rivaroxaban) to 12-17 hours (dabigatran). DOAC exposure increases with age but this 
association is confounded by the influence of age on the kidney function. For instance, 
the area under the concentration-time curve for a single dose of rivaroxaban 10 mg 
increased in average by 41% in healthy elderly persons (weighted mean age 77 years) 
compared to younger persons (weighted mean age 32 years) which was, however, at 
least partially explained by the lower creatinine clearance in the elderly persons 
(weighted mean clearance 55 mL/min versus 121 mL/min) [20]. Similarly, point 
estimates of edoxaban trough levels in patients with atrial fibrillation were higher in the 
elderly, irrespective of dose regimen [21], and edoxaban trough concentrations in 
patients on edoxaban 60 mg daily for atrial fibrillation showed an inverse relationship to 
kidney function [22]. Despite being higher on average, DOAC exposure and trough 
levels in the elderly were within the observed interindividual variability of the overall 
study populations [20, 21, 23-26]. Accordingly, dose adjustment based on age was not 
required in any of the phase III DOAC trials for VTE treatment. Of note, the product 
monograph of dabigatran recommends adjusting the dose of dabigatran to 110 mg twice 
daily for VTE treatment in patients aged 80 years and older, and in those aged 75 years 
and older with one or more risk factors for bleeding. Dabigatran at 110 mg twice daily 
has not been assessed for VTE treatment in a clinical trial, but the recommended dose 
reduction might be justified by results from the pooled analysis of phase III trials for 
treatment of acute VTE which showed that the bleeding risk reduction with dabigatran 
was influenced by age. Compared to vitamin K antagonists (VKAs), dabigatran was 
associated with a reduced risk of bleeding in younger patients but this effect was inverse 
in patients above 85 years in whom VKAs were associated with a lower risk of bleeding 
than dabigatran [27]. 
DOACs have fewer food and drug interactions compared with VKAs; still, such 
interactions have to be considered before prescribing a DOAC [16]. This is particularly 
important in elderly patients since number of medications and co-morbidities increase 
with age. The most relevant drug-drug interactions leading to clinically significant 
alteration in DOAC plasma levels concern drugs metabolized by cytochrome P450 3A4 
in patients on apixaban and rivaroxaban or potent P-glycoprotein inhibitors in patients on 
any DOAC. There are no studies indicating that drug-drug interactions differ between 
elderly and younger patients, but there is insufficient evidence to draw any firm 
conclusions [28]. 
In essence, predictable pharmacodynamics and pharmacokinetics allow for a fixed-
dose regimen across all patients eligible for DOAC treatment. Edoxaban is the only 
DOAC for acute VTE treatment requiring dose adjustment in certain circumstances 
including any one of: impairment of kidney function (i.e., creatinine clearance of 30-50 
mL/min), body weight below 60 kg, and concomitant treatment with potent P-
glycoprotein inhibitors. Whether the dose adjustment of dabigatran in elderly patients as 
recommended in the product monograph is appropriate for treatment of acute VTE has 
not been evaluated in a clinical trial but may be justified by a secondary analysis of the 
RE-COVER trials. On the other hand, inappropriate dose reduction of DOACs during 
initial and long-term VTE treatment occurs more frequently in elderly patients and is 
associated with an increased risk of recurrent VTE [29]. 
 
TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM 
The choice of treatment for acute VTE depends on clinical presentation, site of 
VTE, and benefits and risks of anticoagulation, which should be carefully weighed when 
determining the optimal therapeutic approach. 
 
Thrombolysis 
Hypotension is associated with increased short-term mortality in patients with acute 
PE [30, 31]. Guidelines recommend systemic thrombolysis in such patients to achieve 
rapid improvement of pulmonary obstruction and subsequent reduction of the risk of PE-
related death [10, 11]. This benefit comes at the cost of an increased risk of bleeding, 
which is higher in patients above 75 years than in younger patients (13% vs 3% for 
major bleeding; 1.4% vs 0.5% for intracranial bleeding) [32, 33]. The 2016 ACCP 
guidelines therefore specify that age over 75 years is a relative contraindication to 
thrombolysis while the 2019 ESC guidelines do not make age-specific recommendations 
[10, 11]. Data from the Nationwide Inpatient Sample between 1999 and 2008 indicate 
that unstable elderly patients are less likely to undergo systemic thrombolysis than 
younger patients regardless of presence of co-morbidities [34]. Whether this represents 
undertreatment or appropriate withholding of systemic thrombolysis due to an 
unacceptably high bleeding risk remains to be determined. 
In normotensive PE patients, primary thrombolysis is not recommended in any age 
group [10, 11]. The PEITHO trial randomized hemodynamically stable PE patients with 
increased troponin and right ventricular dysfunction on imaging to systemic thrombolysis 
plus heparin or placebo plus heparin [35]. The risk of death or hemodynamic 
deterioration in patients over 75 years was similar between thrombolysis and placebo 
(4.3% vs 6.7%), but thrombolysis was associated with an increased risk of major 
bleeding (11.1% vs 0.6%) [35]. Preliminary evidence indicates that bleeding risk could 
be mitigated by reduced-dose or catheter-directed thrombolysis,[36, 37] but 
methodologically rigorous trials are required before such treatment can be 
recommended. 
In patient with iliofemoral DVT, catheter-directed thrombolysis in addition to 
anticoagulation reduced the risk of post-thrombotic syndrome at 2 and 5 years of follow-
up in the CAVENT trial [38, 39]. These results were not confirmed in two recent trials 
[40, 41]. The ATTRACT trial which randomized 692 patients with a proximal DVT to 
receive pharmacomechanical thrombolysis (i.e., catheter-directed lysis, mechanical 
thrombus removal, or both) plus anticoagulation or anticoagulation alone, showed no 
difference between the treatment arms with regard to occurrence of recurrent VTE, 
mortality, post-thrombotic syndrome, and quality of life between 6 and 24 months after 
diagnosis [40]. Similar results were seen in the smaller CAVA trial [41]. The lack of 
efficacy and moreover, the increased risk of major bleeding with the addition of catheter-
directed thrombolysis to anticoagulation (3.3% vs. 0%, 1.7% vs. 0.3%, and 5% vs. 0% in 
the CAVENT, ATTRACT and CAVA trial, respectively) [38, 40, 41], support current 
guideline recommendations to consider thrombolysis only if the limb is threatened [10]. 
Given the increased risk of bleeding in elderly patients, this conservative approach can 
likely be extrapolated to patients aged over 75 years who were excluded from the 
CAVENT and ATTRACT trial and underrepresented in the CAVA trial (median age, 52 
years; interquartile range, 38-67 years). 
 
Oral anticoagulants for acute treatment 
In normotensive patients with VTE, anticoagulation is the mainstay of treatment. 
The choice of the optimal anticoagulant agent mainly depends on VTE etiology, kidney 
function, and co-medications. In patients without cancer or severe kidney disease, 
DOACs are the first-choice anticoagulant [10, 11]. Since there are no head-to-head 
DOAC trials, one DOAC cannot be recommended over another [42]. DOACs for acute 
VTE treatment have been compared to VKA therapy in six phase 3 trials using a non-
inferiority study design. The proportion of participants over 75 years ranged from 10% to 
15% across these studies (Table 1), indicating underrepresentation of the elderly 
population as epidemiologic studies show this age group represents approximately 25% 
of the VTE population [43]. While the overall risk of recurrent VTE did not differ between 
elderly and younger patients, concerns of a higher risk of bleeding in elderly patients 
were confirmed in the DOAC trials; there was an almost 3-fold higher risk of major 
bleeding in patients aged over 75 years compared to younger patients, irrespective of 
treatment allocation (Figures 1A and 2A). In patients over 75 years, the risk of recurrent 
VTE was consistently lower in patients on a DOAC compared to those on a VKA with a 
pooled overall relative risk reduction of 44% (95% confidence interval [CI], 0.38-0.82; I2, 
0%; Figure 1B) [13]. This risk reduction was not seen in younger patients (risk ratio, 
0.99; 95% CI, 0.85-1.17; I2, 0%). Similar to younger patients, DOACs were associated 
with a lower risk of major bleeding than VKAs in elderly patients (risk ratio, 0.51; 95% CI, 
0.30-0.85; I2, 60%; Figure 2B) [13]. In summary, the risk of bleeding increased with age 
for both VKAs and DOACs, but DOACs were associated with a lower risk of bleeding 
compared with VKAs. Subgroup analyses of the Hokusai-VTE trial also indicated that 
efficacy of edoxaban as well as its lower risk of bleeding compared to VKA therapy was 
preserved in elderly patients with multimorbidity and polypharmacy [44]. In a large US 
claims database study, frail patients, defined as per the Johns Hopkins Claims-Based 
Frailty Indicator score, were less likely to experience recurrent VTE on rivaroxaban than 
on a VKA with no difference in the risk of bleeding [45]. Post-marketing phase IV trials 
and DOAC registries confirmed that DOACs are safe and effective alternatives to VKAs 
for treatment of VTE in routine clinical practice [46]. Interestingly, the mean age of 
patients enrolled in those studies (range 56-62 years) was similar to that of patients 
enrolled in the large phase III randomized controlled trials (range 55-58 years) [27, 46-
51]. 
In cancer patients, the choice of anticoagulant agent is less obvious and should be 
individualized incorporating patient preferences and values, cancer type, additional risk 
factors for bleeding, and co-medications [52]. In recent randomized controlled trials, 
DOACs for treatment of cancer-associated VTE were associated with a higher risk of 
bleeding (risk ratio, 1.74; 95% CI, 1.05-2.88) and possibly a lower risk of recurrent VTE 
(risk ratio, 0.65; 95% CI, 0.42-1.01) compared to treatment with low-molecular-weight 
heparin [53]. The Hokusai-VTE cancer study is the only randomized controlled trial 
assessing DOACs versus low-molecular-weight heparin for cancer-associated VTE 
which reported results on the subgroup of patients by age (<65 versus ≥65 years, and 
<75 years versus ≥75 years) [54]. The primary composite outcome of recurrent VTE or 
major bleeding did not differ by age [54]. Similar to the findings in the entire study cohort, 
in patients aged 65 years or older, the risk of recurrent VTE appeared to be lower (6.9% 
vs 9.9%) and the risk of major bleeding (8.0% vs 4.2%) to be higher with edoxaban than 
with dalteparin [54]. 
Given that DOAC clearance depends on renal function, patients with severe renal 
failure (i.e., creatine clearance <25-30 mL/min) have been excluded from phase III 
DOAC trials. Therefore, VKAs remain the anticoagulants of choice in these patients. 
Although chronic kidney disease becomes more prevalent with increasing age, severe 
renal failure remains relatively rare in the general elderly population as 3.2% of persons 
aged 75 years or older have an estimated glomerular filtration rate below 30 mL/min [55, 
56]. Retrospective data suggest that apixaban may be associated with lower risks of 
bleeding, thromboembolic events, and mortality compared to VKAs in patients with atrial 
fibrillation and end stage kidney disease [57]. Whether these benefits hold true for 
treatment of VTE in a randomized study is uncertain. Results of the ongoing VERDICT 
study (ClinicalTrials.gov identifier: NCT02664155) will address whether reduced doses 
of apixaban and rivaroxaban for treatment of VTE in patients with moderate to severe 
kidney disease (i.e., 15-50 mL/min) are non-inferior to standard of care (i.e., parenteral 
anticoagulant plus a VKA). While awaiting more data in patients with severe kidney 
disease, we consider DOACs efficacious and safe in patients with non-severe kidney 
disease. Even though the risk of bleeding increases with declining kidney function, 
DOACs were associated with a lower risk of bleeding than VKAs in patients with non-
severe kidney disease without a difference in treatment efficacy [13, 58]. 
 
EXTENDED TREATMENT OF VENOUS THROMBOEMBOLISM 
Duration of treatment 
Once the acute phase of VTE treatment (i.e., first 3 months after diagnosis) is 
completed, determination of whether to continue or stop anticoagulation is based on 
balancing the risks of bleeding and recurrent VTE on and off anticoagulant treatment, 
including associated case-fatality rates. The risk of recurrent VTE is mainly determined 
by the etiology of VTE. Patients with a strong, transient provoking factor (e.g. major 
surgery) are at low risk of recurrence and treatment should be stopped after 3 months 
[10]. Patients with unprovoked VTE are at high risk of recurrence and continuing 
treatment is recommended, unless the risk of bleeding is high [10]. Continuing treatment 
reduces the risk of recurrent VTE by 80-90% while patients are on anticoagulants but 
does not reduce the risk of recurrence once therapy is discontinued [59]. Whether the 
risk of a recurrent VTE after stopping anticoagulation is higher in the elderly remains 
controversial [60-68]. In contrast, the risk of major bleeding was consistently shown to 
be about 2 to 3-fold higher in patients aged above 75 years regardless of anticoagulant 
drug used (Figure 2A) [13, 63, 69]. Similarly, patients with VTE in the context of active 
cancer are at high risk of recurrence and as such, extended treatment is recommended 
for cancer-associated VTE, unless the risk of bleeding outweighs the benefit of 
anticoagulation [10]. This recommendation is mainly based on expert opinion, given that 
only few prospective studies have assessed extended anticoagulant treatment in cancer 
patients [70-74]. There is only one randomized controlled trial that aimed to assess 
anticoagulation versus placebo for extended treatment of cancer-associated VTE but it 
was prematurely terminated due to slow recruitment [74]. 
Although the risk of recurrence after stopping anticoagulation is overall high in 
patients with a first unprovoked VTE (10% in the first year, 25% at 5 years, and 36% at 
10 years) [75], efforts have been made to identify a subgroup of patients with a low 
enough risk to justify stopping anticoagulation after 3-6 months. Because the risk of 
bleeding and possibly the risk of recurrent VTE increase with age, it is uncertain whether 
the generally recommended threshold of an acceptable recurrence risk of 5% in the first 
year after stopping treatment can be applied in the elderly population [76]. Four clinical 
decision rules (HERDOO2, Vienna Prediction Model, DASH, PIT-STOP) have been 
developed to help clinicians determine the risk of recurrence after a first unprovoked 
VTE [65-67, 77]. The only rule which has been validated in a management study is the 
HERDOO2 rule. It allows to identify women at low risk of recurrence based on age, D-
dimer levels, signs of post-thrombotic syndrome, and body mass index [78]. Subgroup 
analyses of the study, however, indicated that among women classified as low-risk, the 
risk of recurrence was substantially higher in women above 50 years (5.7 events per 100 
patient-years) than in women below 50 years (2.0 events per 100 patient-years) [78]. 
Furthermore, the proportion of patients identified at low risk of recurrence is smaller in 
the elderly given that not only age 65 years or older but also other score criteria are 
more frequent in the elderly: advanced age is a risk factor for post-thrombotic syndrome 
[79, 80] and normal D-dimer values are rare in elderly patients with an unprovoked VTE 
[81]. In elderly patients, both the Vienna Prediction Model and the DASH score showed 
poor discriminative power in external validation studies [82, 83], limiting their utility to 
identify a subgroup of elderly patients at low risk of recurrence. No elderly-specific data 
are available for the PIT-STOP model which includes age, sex, site of VTE, and D-dimer 
to generate estimates of recurrent VTE on a continuous scale [77]. 
Not only assessment of the risk of recurrent VTE but also estimation of the risk of 
bleeding is difficult in elderly patients. Several scores have been developed to estimate 
the risk of bleeding in patients on anticoagulants; most of them in cohorts of patients 
with atrial fibrillation. When applied in elderly patients with VTE, the Outpatient Bleeding 
Risk Index, ACCP, HAS-BLED, RIETE, HEMORR2HAGES and ATRIA scores showed 
only poor to moderate discriminative abilities (c-statistics ranging from 0.49 to 0.60) 
when [84, 85]. The VTE-BLEED score was specifically developed to estimate the risk of 
bleeding in patients on anticoagulant treatment beyond 6 months of VTE diagnosis [86], 
but it lacks validation in elderly patients. Seiler et al. have recently proposed a new 
bleeding score which was derived in a cohort of VTE patients aged 65 year or older and 
treated with a VKA [87]. Independent risk factors for major bleeding included in the score 
were previous major bleeding, active cancer, low physical activity, anemia, 
thrombocytopenia, concomitant antiplatelet drug use, and poor INR control [87]. 
However, its use cannot be recommended before external validation studies are 
available, and inclusion of variables specific for VKA treatment may make it less useful 
for patients on DOACs.  
Overall, no validated clinical decision rules are available that help clinicians assess 
the risk of recurrent VTE and bleeding in elderly patients with VTE. Therefore, shared 
decision making which incorporates information on consequences of continuing or 
stopping anticoagulation, and patient preferences and values should be highly 
encouraged in elderly patients.  
Anticoagulants for extended treatment 
When opting for anticoagulant treatment beyond 3 months, the same anticoagulant 
options are available as for acute treatment and guidelines do not suggest to change 
anticoagulant after the first 3 months [10, 11]. VKAs, dabigatran, rivaroxaban and 
apixaban have been specifically evaluated in randomized controlled trials for secondary 
prevention of VTE in patients without cancer. As in the trials for acute VTE treatment, 
the proportion of elderly study participants was below 20% in phase III DOAC trials for 
extended treatment (Table 1). Compared to placebo, active treatment reduced the risk of 
recurrent VTE and increases the risk of bleeding in both younger and elderly patients 
(Figure 3 and 4). The RE-MEDY trial is the only study that specifically compared VKA 
therapy to a DOAC for extended VTE treatment. Overall, dabigatran was non-inferior to 
VKA therapy for preventing recurrent VTE and associated with a lower risk of major and 
clinically relevant non-major bleeding (hazard ratio, 0.54; 95% CI, 0.41-0.71) [88]. Only 
9% of study participants were 75 years or older, and in those 239 patients no recurrent 
VTE occurred in either treatment arm. Subgroup analysis for bleeding events were not 
reported. Rivaroxaban and apixaban are also approved at reduced doses (i.e., 10 mg 
daily for rivaroxaban and 2.5 mg twice daily for apixaban) during extended VTE 
treatment, because they are superior to aspirin and placebo, respectively, for secondary 
prevention of recurrent VTE [89, 90]. Point estimates of risk of recurrent VTE appear to 
be similar in the subgroup of elderly patients, but a limited number of elderly participants 
and low event rates preclude judgment on statistical significance (Figure 3). Low-dose 
aspirin reduces the risk of recurrent VTE by about one third compared to placebo [91]. 
There is, however, little role for aspirin for extended VTE treatment [92], because 
reduced dose rivaroxaban was more efficacious and not associated with a higher risk of 
bleeding than aspirin in the EINSTEIN CHOICE trial [89]. 
Based on the few prospective studies reporting on extended anticoagulant 
treatment for cancer-associated VTE, it seems reasonable to suppose that there is no 
need to change the choice of anticoagulant after the first 3 months [70-74]. None of 
these studies reported subgroup analysis by age. 
 
CONCLUSION 
The incidence of VTE increases with age and elderly patients are at higher risk of 
VTE-related morbidity and mortality. Even though elderly patients are underrepresented 
in clinical trials, extrapolation of study results from younger patients to the elderly 
appears justified for acute VTE treatment and for the choice of anticoagulant agent. 
Subgroup analyses of phase III DOACs trials indicate that during the acute VTE 
treatment phase, DOACs are not only associated with a lower risk of bleeding but even 
appear to be more efficacious than VKAs in preventing recurrent VTE in the elderly.  
The most challenging aspect of VTE management in elderly patients is 
determination of optimal treatment duration. The risk of bleeding increases with age but 
also several risk factors for recurrent VTE are more frequent in the elderly. Clinical 
decision rules to help estimating risk of recurrence and bleeding have only limited utility 
in elderly patients and therefore, shared decision making considering also patient 
preferences and values is essential in determining individualized treatment duration in 
the elderly.  
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Table 1. Phase 3 trials of direct oral anticoagulants for acute and extended treatment of VTE in the subgroup of elderly patients 
Study Design Proportion of 
patients >75 y 
Intervention Control Treatment 
duration 
Primary efficacy 
outcome 
Primary safety 
outcome 
Acute VTE Treatment       
RE-COVER 
pooled [27, 47] 
Double-
blinded 
529/5,107 (10%) LMWH for ≥5 days, then 
dabigatran 150 mg bid 
LMWH for ≥5 days, 
then VKA (INR 2-3) 
6 months Recurrent VTE Not specified 
EINSTEIN 
pooled [48, 49] 
Open-label 1,283/8,281 
(15%) 
Rivaroxaban 15 mg bid for 
21 days, then 20 mg od 
LMWH for ≥5 days, 
then VKA (INR 2-3) 
3, 6, or 12 
monthsb 
Recurrent VTE Clinically relevant 
bleedinga 
AMPLIFY [50] Double-
blinded 
749/5,244 (14%) Apixaban 10 mg bid for 7 
days, then 5 mg bid 
LMWH for ≥5 days, 
then VKA (INR 2-3) 
6 months Recurrent VTE Major bleeding 
Hokusai-VTE 
[51] 
Double-
blinded 
1,104/8,240 
(13%) 
LMWH for ≥5 days, then 
edoxaban 60 mg odc 
LMWH for ≥5 days, 
then VKA (INR 2-3) 
3, 6, or 12 
monthsb 
Recurrent VTE Clinically relevant 
bleedinga 
Extended VTE Treatment       
RE-MEDY [88] Double-
blinded 
259/2,856 (9%) Dabigatran 150 mg bid VKA (INR 2-3) 6-36 
months 
Recurrent VTE Not specified 
RE-SONATE 
[88] 
Double-
blinded 
452/1,343 (33%)d Dabigatran 150 mg bid Placebo 12 months Recurrent VTE Not specified 
EINSTEIN-EXT 
[48] 
Open-label 188/1,196 (16%) Rivaroxaban 20 mg od Placebo 6-12 
months 
Recurrent VTE Major bleeding 
EINSTEIN-
CHOICE [89] 
Double-
blinded 
394/3,365 (12%) Rivaroxaban 20 mg od; 
Rivaroxaban 10 mg od 
Aspirin 100 mg od 
 
6-12 
months 
Recurrent VTE Major bleeding 
AMPLIFY-EXT 
[90] 
Double-
blinded 
329/2,482 (13%) Apixaban 5 mg bid; 
Apixaban 2.5 mg bid 
Placebo 
 
12 months Recurrent VTE 
and all-cause 
death 
Major bleeding 
Abbreviations: bid, twice daily; LMWH; low-molecular-weight heparin; INR, international normalized ratio; od, once daily; VKA, vitamin K antagonist; VTE, venous 
thromboembolism. 
a Clinically relevant bleeding was defined as major bleeding or clinically relevant non-major bleeding. 
b Treatment duration at discretion of the physician. 
c Dose adjustment (edoxaban 30 mg, od) in patients with a creatinine clearance of 30-50 mL/min or a body weight <60 kg, and in patients receiving concomitant 
treatment with potent P-glycoprotein inhibitors. 
d Subgroup analysis for age <65 vs ≥65 years, because subgroup analysis for ≤75 vs >75 years not reported. 
  
Figure 1. Recurrent VTE in DOAC phase 3 trials for acute VTE treatment 
A. Association of recurrent VTE with age over 75 years by treatment arm
 
 
Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism.  
B. Recurrent VTE by age
 
 
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio; VKA, vitamin K antagonist; VTE, venous thromboembolism. 
  
Figure 2. Major bleeding in DOAC phase 3 trials for acute VTE treatment 
A. Association of major bleeding with age over 75 years by treatment arm
 
 
Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist.  
B. Major bleeding by age
 
 
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio; VKA, vitamin K antagonist.  
Figure 3. Primary efficacy outcome in DOAC phase 3 trials for extended VTE treatment by age 
 
 
Abbreviations: CI, confidence interval; RR, risk ratio; VKA, vitamin K antagonist.  
Figure 4. Primary safety outcome in DOAC phase 3 trials for extended VTE treatment by age 
 
 
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; RR, risk ratio. 
